Details of the Drug Combination

General Information of Drug Combination (ID: DCPFLPO)

Drug Combination Name
Indazole derivative 5 Terameprocol
Indication
Disease Entry Status REF
High grade ovarian serous adenocarcinoma Investigative [1]
Component Drugs Indazole derivative 5   DMM1I8R Terameprocol   DMC3P45
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: NCI\\/ADR-RES
Zero Interaction Potency (ZIP) Score: 0.5
Bliss Independence Score: 6.46
Loewe Additivity Score: 6.48
LHighest Single Agent (HSA) Score: 5.21

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ABL T315I mutant (ABL T315I) TTZJTWA ABL1_HUMAN Inhibitor [3]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of Terameprocol
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Terameprocol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Transcription factor Sp1 (SP1) TTZEP6S SP1_HUMAN Modulator [2]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Clear cell renal cell carcinoma DCV87W6 786-0 Investigative [4]
Plasma cell myeloma DCSUAG1 RPMI-8226 Investigative [4]
Renal cell carcinoma DCQNXMZ UO-31 Investigative [4]
Carcinoma DC12K85 RXF 393 Investigative [5]
Colon adenocarcinoma DCUX42S COLO 205 Investigative [5]
Invasive ductal carcinoma DC5OXWP T-47D Investigative [5]
Invasive ductal carcinoma DC217OB BT-549 Investigative [5]
Adenocarcinoma DC9SH51 DU-145 Investigative [1]
Adenocarcinoma DCIMZ2J NCIH23 Investigative [1]
Adenocarcinoma DCVQ2K0 HT29 Investigative [1]
Cutaneous melanoma DC0RCV4 SK-MEL-28 Investigative [1]
High grade ovarian serous adenocarcinoma DCCD82J OVCAR-5 Investigative [1]
Lung adenocarcinoma DCRJ3J5 HOP-62 Investigative [1]
Melanoma DCRTPNL SK-MEL-2 Investigative [1]
Melanoma DCR8L8L MALME-3M Investigative [1]
Non-small cell lung carcinoma DCRHAR1 HOP-92 Investigative [1]
Ovarian serous cystadenocarcinoma DCWZWBU SK-OV-3 Investigative [1]
Pleural epithelioid mesothelioma DCIHAEI NCI-H226 Investigative [1]
Prostate carcinoma DCZHKYJ PC-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 19 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
3 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.